Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

NCT00908349 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
214
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Supernus Pharmaceuticals, Inc.